Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

304 Singh RG, Usha, Rathore SS, Behura SK, Singh NK. Urinary MCP-1 as diagnostic and
prognostic marker in patients with lupus nephritis flare. Lupus 2012; 21: 1214–1218.
305 Chan RW-Y, Lai FM-M, Li EK-M, Tam L-S, Chow K-M, Li PK-T et al. Expression of T-
bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients
predicts disease flare. Rheumatology 2007; 46: 44–8.
306 Bauer J, Petri M, Batliwalla F. Interferon‐regulated chemokines as biomarkers of systemic
lupus erythematosus disease activity: A validation study. Arthritis Rheum 2009; 60: 3098–
3107.
307 Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific
mortality in patients with systemic lupus erythematosus: a meta-analysis of observational
studies. Arthritis Care Res (Hoboken) 2014; 66: 608–616.
308 Ruiz-Irastorza G, Egurbide M-V, Martinez-Berriotxoa A, Ugalde J, Aguirre C.
Antiphospholipid antibodies predict early damage in patients with systemic lupus
erythematosus. Lupus 2004; 13: 900–905.
309 Mak A, Cheung MW-L, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of
systemic lupus erythematosus: meta-analysis and meta-regression of observational studies
from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830–839.
310 Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics
(SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013; 43:
352–361.
311 Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza C a, Alfaro-Lozano JL,
Cucho-Venegas JM et al. The number of flares patients experience impacts on damage
accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204620.
312 Petri M, Purvey S, Fang H, Magder L. Predictors of organ damage in systemic lupus
erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64: 4021–4028.
313 Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic
lupus erythematosus with and without a prolonged serologically active clinically quiescent
period. Arthritis Care Res (Hoboken) 2012; 64: 511–518.
314 Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K et al. Treatto-target
in systemic lupus erythematosus: recommendations from an international task
force. Ann Rheum Dis 2014; 73: 958–967.
315 Pego-Reigosa J, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-
Fernández S et al. Efficacy and Safety of Nonbiologic Immunosuppressants in the
Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. Arthritis
Care Res (Hoboken) 2013; 65: 1775–1185.
316 Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable
response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003;
12: 3–7.
458 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS